Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors not yet licensed by the MHRA or EMA for use in the UK
Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetics patients: variations with increasing levels of HbA1c
Retatrutide vials are typically available in 10 mg or 20 mg configurations
Department of Veterans Affairs databases, at a median follow-up of 3.6 years
Secretagogue A GLP-1 agonist (like Ozempic) mimics the hormone
To further note, in the field of weight-loss treatment, significant work is underway in parallel, on GIP agonist, amylin agonist, glucagon agonist, PYY agonist, either separately or in combination especially with GLP-1 agonist